Saltar al contenido
Sin resultados
Zonamedica
Zonamedica
  • Uncategorized

Texas Drops Claims That Epic Restricted Parents’ Access to Teens’ MyChart Records but Keeps Antitrust Case Alive

Texas withdrew claims that Epic used deceptive MyChart settings to limit parents' access to teenagers' records, but its broader antitrust lawsuit against the health-records company continues.
  • admin
  • noviembre 17, 2026
  • Uncategorized

Retatrutide Cut Sleep Apnea Breathing Events Up to 60.6% in Lilly Trial, but the Weekly Shot Remains Unapproved

Eli Lilly said retatrutide reduced sleep apnea breathing events by up to 60.6% after 80 weeks, but the investigational drug remains unapproved and key trial details have not been published.
  • admin
  • noviembre 17, 2026
  • Uncategorized

Federal Rural Health Fund Gives Rhode Island $6,390 per Rural Resident While Texas Gets About $70

A KFF analysis shows major disparities in second-year Rural Health Transformation Program payments, with Texas receiving about $70 per rural resident and Rhode Island about $6,390.
  • admin
  • noviembre 17, 2026
  • Uncategorized

Medetomidine Withdrawal Gets New National Treatment Guidance as Fentanyl Additive Turns Up in at Least 18 States

New ASAM clinical considerations outline how clinicians should treat medetomidine intoxication and withdrawal, which can cause dangerous cardiovascular symptoms when mixed into illicit fentanyl.
  • admin
  • noviembre 17, 2026
  • Uncategorized

DEA Puts Narcolepsy Pill Orzeyful in Schedule IV as Takeda Launches It in U.S. at $16,500 per Bottle

Takeda launched Orzeyful in the United States at a list price of $16,500 per 60-tablet bottle after the DEA classified its active ingredient as a Schedule IV drug.
  • admin
  • noviembre 17, 2026
  • Uncategorized

Nearly Half of New Semaglutide and Tirzepatide Weight-Loss Users Stayed on Low Doses Through Their First Six Months

An observational study found that nearly half of new semaglutide and tirzepatide users remained on low doses during six months, potentially reflecting tolerability, cost, access or prescribing decisions.
  • admin
  • noviembre 17, 2026
  • Uncategorized

Alpha-Gal Red Meat Allergy: 95% of Xolair Patients Reported Fewer or Milder Reactions in a Small Early Study

A small preliminary study found that 95% of 64 alpha-gal patients taking Xolair reported fewer or milder reactions, though the drug is not specifically approved for the allergy.
  • admin
  • noviembre 17, 2026
  • Uncategorized

Native Americans Living in Cities Are Exempt From Medicaid Work Rules but May Struggle to Prove It

American Indians and Alaska Natives living in cities are exempt from Medicaid work requirements, but inconsistent state verification systems could cause eligible people to lose coverage.
  • admin
  • noviembre 17, 2026
  • Uncategorized

Gazyva Becomes First FDA-Approved Drug for Primary Membranous Nephropathy, a Rare Autoimmune Disease That Attacks the Kidneys

FDA approved Gazyva for primary membranous nephropathy after it beat tacrolimus in a 142-patient trial. Remission rates and boxed warnings.
  • admin
  • noviembre 17, 2026
  • Uncategorized

Zepbound Lowered Teens’ BMI 18.5% to 21.4% in 72-Week Trial, but Most Had Stomach Side Effects

A phase 3 trial found tirzepatide significantly reduced BMI in teens with obesity over 72 weeks, but most reported side effects and Zepbound is not FDA-approved for adolescents.
  • admin
  • noviembre 17, 2026
Anterior
1 2 3 4 5 6 … 11.586
Siguiente

Copyright © 2026 Zonamedica